Doris M. Ponce, MD

Articles by Doris M. Ponce, MD

Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs

ByDoris M. Ponce, MD,Caroline Seymour,Gabriela S. Hobbs, MD

December 11th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

The Future of Chronic GvHD Treatment

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

August 11th 2023

Expert panelists share final thoughts concerning the future of chronic GvHD treatment, highlighting unmet needs, ongoing trials, and promising therapies.

Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

August 4th 2023

Addressing patient monitoring in chronic GvHD, including therapy adjustment indicators and frequency.

Data-Driven Treatment Selection for Patients with Chronic GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

August 4th 2023

Clinical pearls for community oncologists regarding treatment selection and sequencing in chronic GvHD patients.

A Comprehensive Look at Initial Treatment Options for Chronic GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 28th 2023

Exploring FDA-approved treatment options for patients with chronic GvHD, with a focus on trial data and adverse effects.

Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 28th 2023

Insights on treatment strategies and goals for initial chronic GvHD management, including treatment selection rationale and dosing.

Advancements and Promising Directions in Acute GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 21st 2023

Experienced clinicians discuss the future of acute GvHD treatment, focusing on gaps in patient care and potential therapy options.

Enhancing Patient Care in Acute GvHD: Supportive Measures

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 21st 2023

Supportive care measures for acute GvHD are explored, highlighting strategies to manage symptoms and improve patient well-being.

Treatment Options in Steroid-Refractory Acute GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 14th 2023

Treatment options for steroid refractory acute GvHD, including ruxolitinib efficacy and NCCN guideline adherence, take center stage in the discussion.

Optimal First-Line Treatment Approaches for Acute GvHD

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

July 14th 2023

Subject-matter experts delve into the diagnosis, risk assessment, and treatment selection process for acute GvHD, emphasizing differentiation of refractory disease.

Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

June 23rd 2023

Panelists Hannah Choe, MD, and Bart L Scott, MD share insights concerning prophylaxis in Graft-Versus-Host Disease, including key study data and current standards of care as well as discuss the potential role of biomarkers in GvHD.

Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis

ByMichael R. Bishop, MD, University of Chicago,Hannah Choe, MD,Doris M. Ponce, MD,Bart L. Scott, MD

June 23rd 2023

Moderator Michael Bishop, MD introduces expert panelists and leads an overview of Graft-Versus-Host Disease, covering the differences between chronic and acute conditions, how GvHD is typically diagnosed, and GvHD risk assessment.

GvHD: Advice for Patients

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

February 17th 2023

Experts share their insights and advice on how to best communicate with patients who are actively dealing with acute or chronic GvHD.

Future of Chronic GvHD

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

February 17th 2023

A look into the future of chronic GvHD and which treatment options patients the panel is most excited about.

Treatment Options: Steroid-Refractory GvHD

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

February 10th 2023

Experts define and review treatment options for patients with chronic GvHD that are also steroid refractory.

Treatment Options for Chronic GvHD

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

February 10th 2023

Comprehensive discussion into the available treatment options for patients that present with chronic GvHD.

Defining Chronic Graft vs Host Disease (GvHD)

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

February 3rd 2023

Panel of oncologists define in chronic GvHD and review the typical presentation of a patient.

Novel Agents in Acute GvHD

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

February 3rd 2023

Experts discuss new and exciting agents and combinations that are on the horizon for patients with acute GvHD.

Steroid Refractory Acute GvHD and REACH Trials

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

January 27th 2023

An overview of steroid refractory acute GvHD and a review of the REACH trials that assessed the used of ruxolitinib in patients with GvHD.

Acute GvHD: Clinical Presentation, Risk Factors and Treatment Options

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

January 27th 2023

Experts discuss the clinical presentation, grading system and review treatment options for patients with acute GvHD.

Future of Acute GvHD Prevention

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

January 20th 2023

A look into the future of acute GvHD prevention and discussing the impact of targeting specific organs to help manage GvHD prevention.

Clinical Implications of the Phase III BMT CTN 1703 Trial

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

January 20th 2023

Experts review the Phase III BMT CTN 1703 trial and share how the results of this trial might impact their practice and discuss the role of ATG and abatacept in their practice

Regimens Used for GvHD Prevention

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

January 13th 2023

A brief review of the different regimens used by experts for GvHD prevention at their institutions and discuss the importance of GvHD Prevention.

An Overview of Graft vs Host Disease (GvHD)

ByCorey S. Cutler, MD, MPH, FRCPC,Yi-Bin Chen, MD,Hannah Choe, MD,Doris M. Ponce, MD

January 13th 2023

Expert oncologists define graft vs host disease (GvHD) and discuss which risk factors might increase a patient’s risk of developing GvHD.

Latest Updated Articles

Advancements and Promising Directions in Acute GvHD
Published: July 21st 2023 | Updated:
Defining Chronic Graft vs Host Disease (GvHD)
Published: February 3rd 2023 | Updated:
Treatment Options for Chronic GvHD
Published: February 10th 2023 | Updated:
Clinical Implications of the Phase III BMT CTN 1703 Trial
Published: January 20th 2023 | Updated:
Future of Chronic GvHD
Published: February 17th 2023 | Updated:
Acute GvHD: Clinical Presentation, Risk Factors and Treatment Options
Published: January 27th 2023 | Updated:

Doris M. Ponce, MD

Articles by Doris M. Ponce, MD

Making the Most of New Data in MPN, Leukemia, and GVHD From ASH 2023: Drs Ponce and Hobbs

The Future of Chronic GvHD Treatment

Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD

Data-Driven Treatment Selection for Patients with Chronic GvHD

A Comprehensive Look at Initial Treatment Options for Chronic GvHD

Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies

Advancements and Promising Directions in Acute GvHD

Enhancing Patient Care in Acute GvHD: Supportive Measures

Treatment Options in Steroid-Refractory Acute GvHD

Optimal First-Line Treatment Approaches for Acute GvHD

Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease

Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis

GvHD: Advice for Patients

Future of Chronic GvHD

Treatment Options: Steroid-Refractory GvHD

Treatment Options for Chronic GvHD

Defining Chronic Graft vs Host Disease (GvHD)

Novel Agents in Acute GvHD

Steroid Refractory Acute GvHD and REACH Trials

Acute GvHD: Clinical Presentation, Risk Factors and Treatment Options

Future of Acute GvHD Prevention

Clinical Implications of the Phase III BMT CTN 1703 Trial

Regimens Used for GvHD Prevention

An Overview of Graft vs Host Disease (GvHD)

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies